We Offer Worldwide Shipping
Login Wishlist

β-Alanine

$43

  • Brand : BIOFRON

  • Catalogue Number : BF-A3004

  • Specification : 98%

  • CAS number : 107-95-9

  • Formula : C3H7NO2

  • Molecular Weight : 89.09

  • Volume : 100mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-A3004

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

89.09

Appearance

Powder

Botanical Source

Structure Type

Others

Category

SMILES

C(CN)C(=O)O

Synonyms

IUPAC Name

Density

1.2±0.1 g/cm3

Solubility

H2O : 33.33 mg/mL (374.12 mM; Need ultrasonic)

Flash Point

97.2±22.6 °C

Boiling Point

237.1±23.0 °C at 760 mmHg

Melting Point

202 °C (dec.)(lit.)

InChl

InChI=1S/C3H7NO2/c4-2-1-3(5)6/h1-2,4H2,(H,5,6)

InChl Key

UCMIRNVEIXFBKS-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

2922490000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:107-95-9) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

32139676

Abstract

Inducible gene expression systems are vital tools for the advancement of synthetic biology. Their application as genetically encoded biosensors has the potential to contribute to diagnostics and to revolutionise the field of microbial cell factory development. Currently, the number of compounds of biological interest by far exceeds the number of available biosensors. Here, we address this limitation by developing a generic genome-wide approach to identify transcription factor-based inducible gene expression systems. We construct and validate 15 functional biosensors, provide a characterisation workflow to facilitate forward engineering efforts, exemplify their broad-host-range applicability, and demonstrate their utility in enzyme screening. Previously uncharacterised interactions between sensors and compounds of biological relevance are identified by employing the largest reported library of metabolite-responsive biosensors in an automated high-throughput screen. With the rapidly growing genomic data these innovative capabilities offer a platform to vastly increase the number of biologically detectable molecules.

Title

A genome-wide approach for identification and characterisation of metabolite-inducible systems

Author

Erik K R Hanko 1, Ana C Paiva 2, Magdalena Jonczyk 1, Matthew Abbott 1, Nigel P Minton 1, Naglis Malys 3

Publish date

2020 Mar 5

PMID

31842637

Abstract

Introduction: Netarsudil and latanoprost ophthalmic solution (0.02%/0.005%) is indicated for intraocular pressure (IOP) lowering in open-angle glaucoma (OAG) or ocular hypertension (OHTN). The once-daily agent combines the mechanism of action for each of the individual components and provides a new avenue for long-term intraocular pressure control. This review aims to cover the agent’s current efficacy and safety data and opine as to its role in glaucoma management.Areas covered: This article will cover Phase II-III clinical efficacy and safety data as well as basic science literature pertaining to the agent’s mechanism of action and pharmacodynamics. In selecting articles for inclusion in this review, a literature search using the PubMed database was carried out. Cross-referencing was carried out where applicable. We did not use any date or language restrictions in electronic searches.Expert opinion: Netarsudil and latanoprost ophthalmic solution plays a pivotal role in management of individuals with OAG and OHTN. The agent may be used as first-line therapy to provide substantial IOP-lowering or when additional lowering is indicated and prostaglandins have provided insufficient IOP lowering. The once-daily dosing regimen decreases the risk of inadequate treatment due to nonadherence.

KEYWORDS

Glaucoma treatment; latanoprost; netarsudil; rho-kinase inhibitor; trabecular meshwork.

Title

Netarsudil and latanoprost ophthalmic solution for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension

Author

Ahmad A Aref 1, Lawrence S Geyman 1, Abdel-Rahman Zakieh 2, Humoud M Alotaibi 3

Publish date

2019 Dec;1

PMID

31771148

Abstract

Personalised dosing of performance-enhancing food supplements is a hot topic. β-alanine is currently dosed using a fixed dose; however, evidence suggests that this might favour light compared to heavy subjects. A weight-relative dose seems to reverse this problem. In the present study, a novel dosing strategy was tested. A fragmented dose, composed of a fixed fragment of 800 mg and a weight-relative fragment of 10 mg/kg body weight, was compared to a fixed dose of 1600 mg and a weight-relative dose of 20 mg/kg body weight in a cohort of 20 subjects with a body weight ranging 48-139 kg (79.9 ± 24.4 kg). The results show that, following a fragmented dose, the influence of body weight on the pharmacokinetic response (iAUC) over a 210 min period was absent (r = -0.168; p = 0.478), in contrast to the fixed or weight-relative dose. The pharmacokinetic response also seemed more homogenous (CV% = 26%) following a fragmented dose compared to the fixed (33%) and the weight-relative dose (31%). The primary advantage of the easy-to-calculate fragmented dosing strategy is that it does not systematically favour or impair a certain weight group. Thorough dosage studies are lacking in the current field of sports and food supplements, therefore similar considerations can be made towards other (ergogenic) food supplements.

KEYWORDS

beta-alanine; carnosine; ergogenic; food supplement; personalised nutrition.

Title

Fragmented Dosing of β-alanine Induces A Body Weight-Independent Pharmacokinetic Response

Author

Jan Stautemas 1, Alexia Van de Loock 1, Thibaux Van der Stede 1, Lauren Pringels 1, Wim Derave 1

Publish date

2019 Nov 23


Description :

Empty ...